Erythropoiesis Stimulating Agents (esas) - Renal Disorders

Relevant Publications

Iron Deficiency in Newly Referred Patients With Chronic Renal Failure.

Issue Release: 2024

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.

Issue Release: 2024

The influencing factors of the erythropoietin resistance index and its association with all-cause mortality in maintenance hemodialysis patients.

Issue Release: 2024

Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy.

Issue Release: 2024

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the European Renal Best Practice board of the European Renal Association.

Issue Release: 2024

HSR24-133: Real-World (RW) Effectiveness of Erythropoiesis-Stimulating Agents (ESAs) After Luspatercept in Patients (pts) With Myelodysplastic Syndromes (MDS): A Retrospective Analysis of a Large Healthcare Claims Database in the United States.

Issue Release: 2024

Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis.

Issue Release: 2024

Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis.

Issue Release: 2024

The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis.

Issue Release: 2024

A Randomized Trial of the IMPACT of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.

Issue Release: 2024

Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors.

Issue Release: 2024

Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.

Issue Release: 2024

HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.

Issue Release: 2024

Management of Anaemia in Renal Palliative Care Clinic: A Patient-Centred Approach.

Issue Release: 2024

Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.

Issue Release: 2024

Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance.

Issue Release: 2024

A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes.

Issue Release: 2024

Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents.

Issue Release: 2024

Impact of transferrin saturation on cardiovascular events in non-dialysis-dependent chronic kidney disease patients treated with darbepoetin alfa.

Issue Release: 2024

Discovery of Biomarkers of a Recombinant Human Erythropoietin Administration to Thoroughbred Geldings by Label-Free Proteomics.

Issue Release: 2024

What is the Prognosis for Patients with ESRD?

How do Medications Impact Renal Function?

Can ACE Inhibitors be Used in Acute Kidney Injury?

How Can CKD be Prevented?

What is Microalbuminuria?

What Role Does Early Detection Play in Renal Protection?

What is the Role of the Kidneys?

What is the Prognosis for CKD Patients?

How is Microalbuminuria Diagnosed?

What are the side effects of ARBs?

Erythropoiesis Stimulating Agents (esas) - Renal Disorders

Relevant Publications

Partnered Content Networks

Relevant Topics